ArticleCureus2026
Psoriasis Flare Following Interleukin-17 (IL-17) Inhibition and Recent Streptococcal Infection: A Case Report Highlighting Management Complexity.
Article in Cureus, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Psoriasis is a chronic immune-mediated inflammatory skin disease that has a wide range of clinical manifestations. Biologic agents such as interleukin-17 (IL-17) inhibitors are increasingly used for the management of moderate-to-severe psoriasis due to their ability to achieve similar therapeutic outcomes with better safety profiles than conventional systemic treatments, such as methotrexate or cyclosporine. While typically safer, there is a rare possibility of these agents exacerbating psoriasis. Moreover, a psoriasis flare may occur from various causes, such as an adverse reaction to treatments or streptococcal infections. This case illustrates the complexity of managing psoriasis in patients who have contraindications to systemic treatments, are unresponsive to standard therapies, and may have potential complications from streptococcal infection. It highlights the need to consider multiple therapeutic approaches, including the use of phosphodiesterase 4 (PDE4) inhibitors. We discuss the case of a 37-year-old female with worsening of psoriasis following a streptococcal infection and treatment with ixekizumab.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.